$21.49
+0.32 (+1.51%)
Open$21.19
Previous Close$21.17
Day High$21.83
Day Low$21.04
52W High$22.88
52W Low$8.22
Volume—
Avg Volume154.8K
Market Cap286.13M
P/E Ratio—
EPS$-0.27
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+11.6% upside
Current
$21.49
$21.49
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 104.76M | 116.76M | 23.45M |
| Net Income | -10,103,014 | -10,134,543 | 5.38M |
| Profit Margin | -9.6% | -9.2% | 22.9% |
| EBITDA | -5,273,858 | -5,584,223 | 8.65M |
| Free Cash Flow | — | — | 4.59M |
| Rev Growth | -10.3% | -10.3% | -4.1% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |